Land: Singapore
Språk: engelsk
Kilde: HSA (Health Sciences Authority)
TIBOLONE
ORGANON SINGAPORE PTE. LTD.
G03CX01
2.5 mg
TABLET
TIBOLONE 2.5 mg
ORAL
Prescription Only
N V ORGANON
ACTIVE
1991-02-18
RA 1850 S9 REF 12.0 1 1. NAME OF THE MEDICINAL PRODUCT Livial 2.5 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg of tibolone. For excipients, see 6.1. 3. PHARMACEUTICAL FORM Tablet. White, round and flat tablets with beveled edges and a diameter of 6 mm and coded “MK” above “2” on one side and “Organon∗” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Treatment of estrogen deficiency symptoms in postmenopausal women, more than one year after menopause. For all women the decision to prescribe Livial should be based on an assessment of the individual patient’s overall risks and, particularly in the over 60s, should include consideration of the risk of stroke (see sections 4.4 and 4.8). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage is one tablet per day. No dose adjustment is necessary for the elderly. The tablets should be swallowed with some water or other drink, preferably at the same time every day. For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used. A separate progestogen should not be added with Livial treatment. STARTING LIVIAL Women experiencing a natural menopause should commence treatment with Livial at least 12 months after their last natural bleed. In case of a surgical menopause, treatment with Livial may commence immediately. Any irregular/unscheduled vaginal bleeding, either on or off HRT, should be investigated to exclude malignancy before starting Livial (see section 4.3). SWITCHING FROM A SEQUENTIAL OR CONTINUOUS COMBINED HRT PREPARATION If changing from a sequential HRT preparation, treatment with Livial should start the RA 1 Les hele dokumentet
RA 1850 S9 REF 12.0 1. NAME OF THE MEDICINAL PRODUCT Livial® 2.5 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg of tibolone. For excipients, see 6.1. 3. PHARMACEUTICAL FORM Tablet. White, round and flat tablets with beveled edges and a diameter of 6 mm and coded “MK” above “2” on one side and “Organon ” on the other side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications • Treatment of estrogen deficiency symptoms in postmenopausal women, more than one year after menopause. For all women the decision to prescribe Livial should be based on an assessment of the individual patient’s overall risks and, particularly in the over 60s, should include consideration of the risk of stroke (see sections 4.4 and 4.8). 4.2 Posology and method of administration The dosage is one tablet per day. No dose adjustment is necessary for the elderly. The tablets should be swallowed with some water or other drink, preferably at the same time every day. For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used. A separate progestagen should not be added with Livial treatment. Starting Livial Women experiencing a natural menopause should commence treatment with Livial at least 12 months after their last natural bleed. In case of a surgical menopause, treatment with Livial may commence immediately. Any irregular/unscheduled vaginal bleeding, either on or off HRT, should be investigated to exclude malignancy before starting Livial (see section 4.3). Switching from a sequential or continuous combined HRT preparation If changing from a sequential HRT preparation, treatment with Livial should start the day following completion of the prior regimen. If changing from a continuous-combined HRT preparation, treatment can start at any time. Missed dose A missed dose should be taken as soon as remembered, unless it is more than 12 hours overdue. In the latter case, the missed dose should Les hele dokumentet